Smith-McCune Karen K, Tuveson Jennifer L, Rubin Mary M, Da Costa Maria M, Darragh Teresa M, Shiboski Stephen C, Van Der Pol Barbara, Moscicki Anna-Barbara, Palefsky Joel M, Sawaya George F
Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, CA 94143-0128, USA.
J Low Genit Tract Dis. 2006 Oct;10(4):213-8. doi: 10.1097/01.lgt.0000225889.13916.c6.
Little is known about effects of vaginal lubricants with barrier contraceptives on detection of sexually transmissible infections. We hypothesized that Replens gel used with a diaphragm would neither inhibit human papillomavirus (HPV) detection in cervical samples and chlamydia (CT) and gonorrhea (GC) detection in urine samples, nor affect cervical cytology quality.
After a clinician-collected cervical sample and a self-collected vaginal sample for HPV detection ("pregel" specimens), women placed a diaphragm containing Replens gel into the vagina. Participants (n = 77) removed the diaphragm after 6 hours and performed vaginal HPV self-sampling at several time points thereafter. Clinicians performed cervical cytology sampling and HPV testing ("postgel" specimens) 24 hours after diaphragm removal. Pregel and postgel specimens were analyzed with and without added SiHa cells (source of defined numbers of HPV16 genomes). HPV was detected by polymerase chain reaction using MY09/11 primers. Urine samples were obtained for CT and GC testing. Proportions of samples testing positive were compared using relative risk (RR) regression models.
Proportions with detectable HPV in the clinician-collected cervical pregel and postgel samples were not statistically different for samples with added SiHa cells (88.3% vs 93.2%, RR = 1.06, 95% confidence interval = 0.96-1.14) or for native HPV infection (32.9% vs 28.2%, RR = 0.87, 95% confidence interval = 0.71-1.06). In self-collected vaginal postgel samples, there was no trend for decreased HPV detection after gel exposure. Gel affected neither urine tests for CT and GC nor cytological quality.
Recent Replens gel use with a diaphragm does not inhibit cervical HPV testing, urine testing for CT and GC, or cervical cytology quality.
关于阴道润滑剂与屏障避孕法联合使用对性传播感染检测的影响，目前所知甚少。我们假设，与隔膜一起使用的Replens凝胶既不会抑制宫颈样本中人类乳头瘤病毒（HPV）的检测，也不会抑制尿液样本中衣原体（CT）和淋病奈瑟菌（GC）的检测，同时也不会影响宫颈细胞学检查的质量。
在临床医生采集宫颈样本和自行采集阴道样本用于HPV检测（“凝胶前”样本）后，女性将含有Replens凝胶的隔膜放入阴道。参与者（n = 77）在6小时后取出隔膜，并在之后的几个时间点进行阴道HPV自我采样。临床医生在取出隔膜24小时后进行宫颈细胞学采样和HPV检测（“凝胶后”样本）。对添加和未添加SiHa细胞（特定数量HPV16的来源）的“凝胶前”和“凝胶后”样本进行分析。使用MY09/11引物通过聚合酶链反应检测HPV。采集尿液样本用于CT和GC检测。使用相对风险（RR）回归模型比较检测呈阳性样本的比例。
对于添加了SiHa细胞的样本（88.3%对93.2%，RR = 1.06，95%置信区间 = 0.96 - 1.14）或自然HPV感染样本（32.9%对28.2%，RR = 0.8
